Pure Biologics Spólka Akcyjna
PUR.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.20 | -0.02 | 0.67 |
| FCF Yield | -12.26% | -58.14% | -45.31% | -14.30% |
| EV / EBITDA | -8.34 | -1.90 | -2.27 | -19.70 |
| Quality | ||||
| ROIC | -1,311.76% | -213.86% | -119.26% | -27.24% |
| Gross Margin | 0.00% | -2,709.47% | -816.77% | -1,585.43% |
| Cash Conversion Ratio | 0.56 | 0.65 | 0.68 | 2.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -27.95% | 4.99% | -75.25% |
| Free Cash Flow Growth | 53.80% | -1.27% | 6.33% | -1,190.91% |
| Safety | ||||
| Net Debt / EBITDA | -1.12 | -0.36 | -0.03 | 0.36 |
| Interest Coverage | -9.31 | -8.27 | -74.86 | -46.18 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,752.50 | 56,511.39 | 7,954.36 | 13,292.34 |